BioMarin Pharmaceutical Inc.
BMRN
NASDAQ·Healthcare·Biotechnology·Mkt cap $12.9B
$66.53
▲ +0.15%
P/E
166.33
Mkt Cap
$12.9B
52-Wk Range
$49.26–$70.98
52-Week Range
$49.26 - $70.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 18.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized rare disease expertise
- Robust clinical development pipeline
- Proprietary genetic treatment technologies
- Strong intellectual property portfolio
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Moderate growth ahead
Expanding rare disease treatment portfolio
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Strong
+17.6% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying BMRN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 26, 2026
AUG 6, 2026
Reported EPS of $1.20 vs $0.95 consensus (+27.0% surprise). Revenue of $989.7M vs $932.0M expected (+6.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.0%
Revenue trend · last 8Q
—
+16%
+15%
+16%
+4%
+17%
+3%
+20%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$745.7M
$747.3M
$745.1M
$825.4M
$776.1M
$874.6M
$766.2M
$989.7M
Margins · last 8Q
Gross
79.5%
Operating
11.2%
Profit
4.5%
Wall Street consensus
14 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Sep 1, 2026
vs Industry
How BMRN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related